Illustrative image – not actual.
Ajanta Pharma has lined up a capex plan of Rs 250 crore for FY22 as it looks to expand its corporate office and production facilities.
The Mumbai-based drug maker operates eight manufacturing facilities in India and Mauritius, including two plants which have been approved by the US Food and Drug Administration (USFDA).
The capex will largely go towards maintenance and some new expansions for the corporate office and some key expansions in the facility.
The company had earmarked a capex plan of Rs 150 crore for FY20. In 2020, the drug maker invested Rs 30 crore in the expansion of the corporate office, and in 2021 it is going to be in the range of Rs 60-80 crore.
Ajanta Pharma currently employs over 7,000 people worldwide and its products are sold in over 30 countries, including the US -- the world's largest market for pharmaceutical products.
